No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
322 |
4. Check minimum number of eventsNone |
322 |
5. Include endpointsNone |
322 |
6. Filter based on genotype QC (FinnGen only) |
322 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D30
- Name in latin
- Neoplasma benignum vesicae urinariae
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Bladder
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Bladder
- Benign neoplasm of urinary organs
- Benign neoplasm of urinary organs
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2475 | 947 | 1483 |
| Only index persons | 1772 | 757 | 1015 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.03 | 0.04 |
| Only index persons | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 63.13 | 60.11 | 64.96 |
| Only index persons | 61.04 | 57.95 | 63.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 322 | 113 | 209 |
| Unadjusted period prevalence (%) | 0.07 | 0.04 | 0.09 |
| Median age at first event (years) | 62.30 | 55.24 | 66.11 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 295
- Matched controls
- 2944
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D30.3
ICD-10 Finland
Benign neoplasm: Bladder
+∞
307.9
239
*
UKC02
NOMESCO Finland
Cystoscopy
21.9
117.4
224
370
KCD02
NOMESCO Finland
Transurethral resection of bladder
43.2
93.8
117
44
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
41.6
58.6
73
23
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
19.5
42.0
65
42
R31
ICD-10 Finland
Unspecified haematuria
7.0
38.6
111
234
2233A
ICD-9 Finland
Benign neoplasm of kidney and other urinary organs, Bladder
+∞
37.3
35
*
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
35.1
35.0
45
15
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
24.6
33.9
48
23
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
20.5
33.3
50
29
22330
ICD-8 Finland
Benign neoplasm of kidney and other urinary organs, Bladder
+∞
27.5
26
*
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
32.8
27.0
35
12
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
24.0
26.9
38
18
7323
FHL
Electrosection of TU bladder wall change
94.6
24.1
26
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
22.4
23.6
34
17
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
47.3
21.8
26
6
1530
FHL
Urethrocystoscopy
11.2
18.5
35
35
8120/1-C67.9
ICD-O-3
Urothelial papilloma, NOS, of bladder, NOS
+∞
15.8
15
*
7321
FHL
TU biopsy, coagulation or laser
40.4
15.6
19
5
KCB00
NOMESCO Finland
Biopsy of bladder
33.6
12.7
16
5
WX320
NOMESCO Finland
Spinalanesthesy
2.6
10.5
94
453
C67.1
ICD-10 Finland
Malignant neoplasm: Dome of bladder
41.5
10.0
12
*
J01MA02
ATC
ciprofloxacin; systemic
2.2
9.1
143
895
ZX136
NOMESCO Finland
Intravesicalis
14.6
8.8
14
10
8130/1-C67.9
ICD-O-3
Papillary urothelial neoplasm of low malignant potential of bladder, NOS
51.5
8.7
10
*
18899
ICD-8 Finland
Malignant neoplasm of bladder
92.5
8.5
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
8.4
93
493
1888X
ICD-9 Finland
Malignant neoplasm of bladder, Other specified sites of bladder
34.3
8.1
10
*
C67.0
ICD-10 Finland
Malignant neoplasm: Trigone of bladder
13.5
7.9
13
10
C67.4
ICD-10 Finland
Malignant neoplasm: Posterior wall of bladder
46.2
7.7
9
*
KCW96
NOMESCO Finland
Other operations on bladder
18.9
7.7
11
6
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.5
7.5
34
105
J01EA01
ATC
trimethoprim; systemic
2.2
7.3
86
466
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
10.4
7.1
13
13
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.2
6.2
64
323
R33
ICD-10 Finland
Retention of urine
2.6
6.2
46
198
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
160
950
2.36
12.76
6.5
3.5
—
—
—
0
0
217
1660
1.94
7.05
9.0
4.7
3327.2
535.9
e6/l
—
6
30
162
1171
1.77
5.90
5.5
4.1
0.0
0.0
estimate
0.00
30
222
77
455
1.91
5.36
6.5
2.9
1.5
1.1
e6/l
0.24
53
263
162
1193
1.72
5.35
5.6
4.1
0.0
0.0
estimate
0.00
30
213
107
704
1.78
5.26
2.3
2.0
2.6
3.2
mg/l
2.08
91
604
159
1174
1.70
5.14
7.6
5.5
0.0
0.0
estimate
0.00
30
221
111
750
1.73
4.92
7.3
3.4
0.2
0.5
e6/l
3.27
90
571
73
440
1.85
4.74
7.0
3.1
2.8
2.0
e6/l
0.23
49
251
137
992
1.66
4.63
3.2
2.7
146.5
151.8
ug/l
0.08
127
910
64
378
1.86
4.41
2.7
2.4
18.3
22.3
%
2.13
55
332
166
1278
1.61
4.30
7.3
6.6
1.2
1.2
mmol/l
0.63
136
1068
66
399
1.82
4.22
2.6
2.4
2.3
2.3
g/l
0.25
61
364
70
441
1.75
3.88
2.5
2.3
12.0
12.7
umol/l
0.26
64
404
149
1138
1.57
3.86
4.9
4.0
—
—
—
0
0
150
1170
1.53
3.41
5.6
6.0
1.2
1.2
mmol/l
0.44
136
1047
10
27
3.79
3.37
1.9
2.1
—
—
—
0
0
78
525
1.64
3.36
5.4
4.3
1.0
1.0
kg/l
0.30
18
82
183
1494
1.52
3.33
5.4
4.7
6.9
6.8
mmol/l
0.21
174
1395
169
1373
1.48
3.04
10.8
9.1
4.1
4.4
e9/l
0.57
149
1187
59
380
1.67
3.00
31.8
25.9
1.4
1.4
inr
0.00
13
49
164
1331
1.47
2.93
7.5
6.2
11.2
12.0
umol/l
0.81
158
1253
6
9
6.76
2.87
1.2
1.1
—
—
—
0
0
33
184
1.88
2.72
1.8
1.5
—
—
—
0
0
117
909
1.45
2.54
6.1
4.3
—
—
—
0
0
5
8
6.32
2.38
2.2
9.1
—
—
—
0
0
19
91
2.15
2.37
2.4
4.6
—
2.7
—
0
11
79
580
1.48
2.27
1.7
1.8
1014.1
1142.6
nmol/l
0.73
59
442
48
317
1.60
2.22
1.9
1.7
—
—
—
0
0
28
159
1.83
2.21
1.3
1.4
—
—
—
0
0
79
586
1.46
2.15
1.8
1.7
398.9
11728833.2
pmol/l
0.50
63
486
29
169
1.78
2.11
2.4
1.7
—
—
—
0
0
8
26
3.12
2.02
3.4
1.3
—
—
—
0
0
195
1703
1.36
1.97
4.5
3.6
14.9
14.9
pmol/l
0.06
172
1497
104
823
1.39
1.96
4.7
4.0
10.0
11.5
mg/mmol
0.18
66
520
80
607
1.42
1.92
3.0
2.3
—
—
—
0
0
266
2456
1.47
1.86
26.9
19.3
139.7
139.6
mmol/l
0.15
260
2380
13
59
2.25
1.86
1.4
1.6
—
—
—
0
0
257
2359
1.44
1.85
24.7
16.4
23.0
26.4
mg/l
1.01
224
1934
98
775
1.38
1.84
3.2
2.3
50.6
55.6
u/l
0.99
93
713
14
66
2.17
1.84
1.4
1.6
0.3
0.0
iu/ml
—
5
18
266
2459
1.46
1.82
27.1
19.5
4.0
4.0
mmol/l
0.30
259
2381
64
472
1.44
1.78
2.2
1.8
—
—
—
0
0
46
318
1.52
1.76
2.0
1.8
—
—
—
0
0
18
96
1.92
1.74
2.8
3.3
—
—
—
0
0
145
1229
1.32
1.71
2.7
2.6
—
—
—
0
0
130
1085
1.33
1.70
2.7
2.1
94.9
91.3
pmol/l
0.40
62
577
87
683
1.37
1.70
3.4
2.9
373.9
8801.2
umol/l
3.47
72
579
12
55
2.22
1.69
1.4
1.5
—
—
—
0
0
5
14
3.61
1.62
2.4
2.4
—
—
—
0
0
110
902
1.33
1.61
3.6
3.2
1858.6
1708.7
ng/l
0.15
93
777
42
291
1.51
1.60
4.3
3.6
—
—
—
0
0
83
654
1.36
1.58
5.7
4.3
0.0
0.0
estimate
0.00
30
216
13
64
2.07
1.56
1.7
1.7
—
—
—
0
0
8
33
2.46
1.54
1.6
1.5
—
—
—
0
0
28
178
1.63
1.54
6.1
3.2
1.9
1.6
mmol/l
0.13
21
130
34
227
1.55
1.53
4.9
6.8
1.5
1.3
mmol/l
0.47
34
211
134
1138
1.30
1.51
6.6
4.5
34.2
34.9
g/l
0.82
126
1069
12
58
2.11
1.50
2.3
2.3
122.2
124.5
g/l
—
6
41
19
109
1.79
1.49
2.4
1.7
—
—
—
0
0
199
1782
1.30
1.49
5.8
4.1
15.4
13.7
mm/h
0.63
188
1609
104
857
1.31
1.46
4.0
3.2
2.4
2.3
mmol/l
0.27
86
738
5
16
3.15
1.44
1.4
1.1
—
—
—
0
0
5
16
3.15
1.44
1.2
1.2
—
—
—
0
0
5
16
3.15
1.44
1.4
1.1
—
—
—
0
0
45
324
1.45
1.43
5.4
6.6
0.5
1.1
mmol/l
0.56
36
259
35
244
1.49
1.32
5.2
3.8
1.4
1.6
mmol/l
0.17
30
186
8
35
2.31
1.27
1.5
1.6
—
—
—
0
0
231
2132
1.29
1.26
5.7
4.4
2.1
2.0
mu/l
0.25
210
1879
5
19
2.65
1.22
1.8
1.4
—
—
—
0
0
47
354
1.38
1.19
7.2
6.4
105.2
104.2
mmol/l
0.83
47
344
11
57
1.96
1.18
1.8
2.6
13.8
15.2
%
—
6
30
160
1422
1.25
1.17
4.7
3.0
59.7
53.6
u/l
0.34
152
1307
66
527
1.32
1.15
5.5
3.8
237.4
235.8
ng/l
0.00
58
437
235
2184
1.28
1.15
7.5
6.5
41.8
40.9
mmol/mol
0.74
219
2001
8
40
2.02
1.12
1.6
1.5
—
—
—
0
0
6
123
0.48
1.07
1.2
1.8
—
—
—
0
0
7
33
2.14
1.06
2.9
1.6
13.2
15.9
ug/l
—
7
33
5
22
2.29
1.03
2.2
1.4
—
—
—
0
0
27
189
1.47
1.02
4.0
2.9
54.0
61.3
ml/min/173m2
—
8
79
137
1211
1.23
1.02
6.0
5.5
2.3
3.1
ug/l
1.06
123
1070
30
216
1.43
0.99
2.5
2.0
378.8
390.6
nmol/l
0.10
25
197
56
447
1.30
0.98
1.3
1.2
0.6
1.7
u/ml
1.29
12
115
124
1088
1.22
0.98
5.1
4.0
35.3
54.9
ng/l
1.48
94
834
5
23
2.19
0.98
1.0
1.1
—
—
—
0
0
5
23
2.19
0.98
1.0
1.1
—
—
—
0
0
7
37
1.91
0.94
1.3
1.1
—
—
—
0
0
6
28
2.16
0.92
3.7
3.2
—
—
—
0
0
8
43
1.88
0.88
1.6
1.6
—
—
—
0
0
80
678
1.24
0.87
2.0
1.6
21.3
20.1
nmol/l
0.28
67
562
6
32
1.89
0.82
1.3
1.5
—
—
—
0
0
6
32
1.89
0.82
1.2
1.5
—
—
—
0
0
6
32
1.89
0.82
1.3
1.5
—
—
—
0
0
231
2177
1.21
0.81
4.5
4.3
1.4
1.3
mmol/l
1.46
206
1959
6
33
1.83
0.79
1.3
1.5
—
—
—
0
0
6
33
1.83
0.79
1.3
1.5
—
—
—
0
0
6
33
1.83
0.79
1.3
1.5
—
—
—
0
0
6
33
1.83
0.79
1.0
1.4
—
—
—
0
0
18
123
1.49
0.79
2.4
1.8
—
—
—
0
0
0
26
0.00
0.78
0.0
1.7
—
—
—
0
0
0
26
0.00
0.78
0.0
1.7
—
—
—
0
0
0
26
0.00
0.78
0.0
1.7
—
—
—
0
0
106
935
1.20
0.78
2.7
2.3
76.1
76.4
nmol/l
0.04
96
809
18
124
1.48
0.76
4.8
4.1
23.8
23.7
mmol/l
0.09
18
112
10
59
1.72
0.76
1.9
1.6
—
—
—
0
0
9
56
1.62
0.73
1.8
1.3
—
—
—
0
0
11
68
1.64
0.72
1.3
1.6
—
—
—
0
0
20
143
1.42
0.71
1.5
2.0
—
—
—
0
0
5
27
1.86
0.68
2.2
1.4
—
—
—
0
0
41
335
1.25
0.63
1.4
1.3
40.5
13.6
u/ml
0.50
17
116
8
49
1.65
0.62
1.0
1.3
—
—
—
0
0
5
30
1.67
0.61
1.2
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
32
256
1.28
0.59
2.4
2.5
4.6
8.9
ug/l
1.30
24
223
16
115
1.41
0.57
1.9
2.9
—
—
—
0
0
42
349
1.23
0.57
4.8
4.9
32.3
32.1
%
0.03
27
227
6
36
1.68
0.57
1.7
1.6
—
—
—
0
0
256
2465
1.18
0.56
14.5
11.0
25.2
25.2
u/l
0.00
247
2357
35
286
1.25
0.55
1.4
1.4
—
—
—
0
0
14
99
1.43
0.55
1.0
1.0
—
—
—
0
0
9
62
1.46
0.53
1.1
1.3
—
—
—
0
0
237
2273
1.16
0.52
5.1
4.8
4.4
4.4
mmol/l
0.57
213
2070
42
353
1.22
0.52
1.2
1.3
22.2
38.6
iu/ml
1.20
15
119
19
144
1.34
0.51
6.9
9.3
23.7
24.5
mmol/l
0.75
19
135
61
538
1.16
0.45
1.7
1.7
0.9
1.4
mg/l
2.42
47
425
230
2211
1.14
0.45
23.4
15.7
72.9
75.3
ml/min/173m2
0.89
201
1819
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
86
1.41
0.45
2.9
2.3
0.3
0.4
u/ml
—
6
46
241
2325
1.14
0.44
5.5
5.3
2.5
2.6
mmol/l
0.32
216
2100
234
2254
1.13
0.44
5.1
4.7
1.4
1.4
mmol/l
1.52
209
2036
10
70
1.44
0.42
1.2
1.5
—
—
—
0
0
36
306
1.20
0.41
3.1
4.4
3.9
47.2
ug/l
1.03
30
261
5
33
1.52
0.41
2.2
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
8
59
1.36
0.41
1.9
1.6
—
—
—
0
0
11
79
1.40
0.41
2.3
3.6
0.0
0.0
g/l
0.00
11
72
0
17
0.00
0.40
0.0
1.2
—
—
—
0
0
5
35
1.43
0.39
1.0
1.2
—
—
—
0
0
236
2284
1.12
0.37
5.7
4.9
6.3
6.1
mmol/l
1.58
215
2053
11
81
1.37
0.36
2.3
3.5
0.0
0.0
g/l
0.00
11
73
209
2012
1.11
0.35
26.0
17.9
38.8
38.9
%
0.05
131
1304
6
45
1.34
0.34
1.5
1.4
—
—
—
0
0
6
45
1.34
0.34
2.0
1.6
—
—
—
0
0
6
47
1.28
0.32
2.2
1.4
—
—
—
0
0
11
83
1.34
0.32
1.1
1.2
—
—
—
0
0
7
54
1.30
0.30
1.9
2.0
—
—
—
0
0
66
604
1.11
0.30
1.8
1.7
1.4
1.3
mmol/l
0.31
59
495
9
118
0.75
0.28
3.8
2.9
11.8
2508.0
u/ml
—
9
101
8
67
1.20
0.26
1.6
1.3
—
—
—
0
0
11
86
1.29
0.26
2.3
3.4
0.0
0.0
g/l
0.00
11
78
12
96
1.26
0.24
3.8
3.9
4.0
4.0
mmol/l
0.07
12
87
19
221
0.85
0.23
1.6
1.4
—
—
—
0
0
36
324
1.12
0.22
11.0
7.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
9.0
—
0
10
0
12
0.00
0.21
0.0
2.3
—
13.8
—
0
12
0
13
0.00
0.21
0.0
3.9
—
—
—
0
0
0
13
0.00
0.21
0.0
3.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
7
61
1.15
0.17
1.3
1.3
—
—
—
0
0
11
91
1.21
0.17
2.4
3.3
38.5
37.3
g/l
0.31
11
76
15
129
1.17
0.17
1.7
1.8
—
—
—
0
0
66
688
0.95
0.12
4.1
3.2
0.8
0.8
ug/l
0.10
50
489
5
46
1.09
0.09
1.4
1.9
—
—
—
0
0
11
97
1.14
0.09
2.3
3.3
0.1
0.8
g/l
1.44
11
85
6
57
1.05
0.08
1.2
1.4
—
—
—
0
0
6
57
1.05
0.08
1.2
1.4
—
—
—
0
0
7
65
1.08
0.08
1.0
1.2
—
—
—
0
0
7
66
1.06
0.08
1.0
1.2
—
—
—
0
0
8
91
0.87
0.07
1.1
1.3
—
—
—
0
0
50
515
0.96
0.05
4.5
3.2
2.5
2.5
mmol/l
1.00
42
454
97
962
1.01
0.01
5.5
4.7
20.3
21.5
%
0.46
51
501
0
8
0.00
0.00
0.0
1.3
—
1.3
—
0
8
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
0.00
0.0
6.4
—
116.8
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_BLADDER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BLADDER | 1.365 [1.11, 1.68] | 0.004 |
| Birth year | 0.991 [0.98, 1.0] | 0.048 |
During the follow-up period (1.1.1998 — 31.12.2019), 171 out of 564 females with CD2_BENIGN_BLADDER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BLADDER | 1.415 [1.17, 1.7] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 343 out of 846 males with CD2_BENIGN_BLADDER died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_BLADDER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.114% | 0.309% |
| 5 | 0.766% | 1.871% |
| 10 | 1.776% | 4.391% |
| 15 | 3.311% | 8.048% |
| 20 | 5.832% | 13.67% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_BLADDER – Benign neoplasm: Bladder
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data